Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety DisorderBusiness Wire • 09/23/24
All You Need to Know About VistaGen Therapeutics (VTGN) Rating Upgrade to BuyZacks Investment Research • 09/06/24
VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 08/13/24
Vistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate UpdateBusiness Wire • 08/13/24
Vistagen to Report Fiscal Year 2025 First Quarter Results and Host Corporate Update Conference Call on August 13, 2024Business Wire • 08/06/24
Vistagen Broadens PH80 Global Intellectual Property Portfolio with New Patents for the Treatment of MigraineBusiness Wire • 07/09/24
Vistagen Awarded Mental Health America's Platinum Bell Seal for Workplace Mental Health for the Second Consecutive YearBusiness Wire • 06/27/24
Vistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate UpdateBusiness Wire • 06/11/24
Vistagen to Report Fiscal Year 2024 Financial Results and Host Corporate Update Conference Call on June 11, 2024Business Wire • 06/07/24
Vistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) ConferenceBusiness Wire • 05/23/24
Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare ConferenceBusiness Wire • 05/07/24
Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental FatigueBusiness Wire • 04/25/24
Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) ConferenceBusiness Wire • 04/09/24
Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2Business Wire • 04/01/24
Why VistaGen Therapeutics Is A Buy: Fasedienol Potential For Anxiety TreatmentsSeeking Alpha • 03/17/24